Bioinvest.com

THOUSAND OAKS, Calif., April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® ...

Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking SessionCorlanor® (Ivabradine) Chronic Heart Failure Data to be Presented in an Oral Abstract Session THOUSAND OAKS, Calif., March...

Technology (+0.7%) finished the day in line with the benchmark index. Visa (V 86.08, +3.78) was the sector’s top performer thanks to better than expected earnings and revenue. However, lackluster performances from large-cap components like Apple (AAPL...

by Jake Bernstein This story was co-published with The Daily Beast Michael Retsky awoke from surgery to bad news. The tumor in his colon had spread to four of his lymph nodes and penetrated the bowel wall. When Retsky showed the pathology report to...

Big Pharma’s focus on blockbuster cancer drugs squeezes out cheaper treatments. The result, one researcher says: ‘If we’re winning the war on cancer, we’re not winning that fast.’ Michael Retsky awoke from surgery to bad...